 |
|
Ethical, Behavioral, and Social Aspects of HIV Vaccine Trials in Developing Countries
Peter Lurie, MD, MPH;
Makonnen Bishaw, PhD;
Margaret A. Chesney, PhD;
Molly Cooke, MD;
Maria Eugenia Lemos Fernandes, MD;
Norman Hearst, MD, MPH;
Edward Katongole-Mbidde, MD;
Suporn Koetsawang, MD;
Christina P. Lindan, MD;
Jeffrey Mandel, PhD, MPH;
Marvellous Mhloyi, PhD;
Thomas J. Coates, PhD
JAMA. 1994;271(4):295-301.
Abstract
| |
Issue.
—Several investigators are preparing to conduct efficacy trials of human immunodeficiency virus (HIV) vaccines in the developing world. Failure to adequately address the unique ethical, behavioral, and social issues that surround vaccine testing in that setting will jeopardize the success of these trials and future acquired immunodeficiency syndrome (AIDS) research in the host nation.
Description of the Project.
—Twelve investigators from Africa, Asia, North America, and South America reviewed previous experience with HIV trials in developing countries and explored potential solutions to these issues.
Conclusions.
—Host country scientists, government officials, and media must be actively involved in all aspects of the trials. Minimum prerequisites for conducting the trial include the following: (1) researching vaccines active against developing world HIV isolates; (2) establishing and maintaining an adequate technological infrastructure; (3) assessing the feasibility of recruitment in countries where the existence of HIV may be denied; (4) designing methods to obtain informed consent from each individual subject, rather than exclusively from family members or community elders; (5) creating locally appropriate instruments to measure risk behavior; (6) identifying a behavioral intervention for placebo and treatment groups; (7) making available laboratory methods to distinguish between natural HIV infection and vaccine-induced seropositivity; and (8) guaranteeing that an effective vaccine is available free of charge to the placebo group and at affordable prices to other host country residents.
(JAMA. 1994;271:295-301)
Author Affiliations
From the Center for AIDS Prevention Studies, University of California, San Francisco (Drs Lurie, Chesney, Cooke, Hearst, Lindan, Mandel, and Coates); the Institute of Development Research, Addis Ababa (Ethiopia) University, (Dr Bishaw); Family Health International/ AIDSCAP, Sao Paulo, Brazil (Dr Fernandes); the Uganda Cancer Institute, Kampala (Dr Katongole-Mbidde); the Siraraj Family Health Research Center, Mahidol University, Bangkok, Thailand (Dr Koetsawang); and the University of Zimbabwe, Harare (Dr Mhloyi).
Footnotes
Reprint requests to the Center for AIDS Prevention Studies, University of California, 74 New Montgomery St, Sixth Floor, San Francisco, CA 94105 (Dr Lurie).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Composition, training needs and independence of ethics review committees across Africa: are the gate-keepers rising to the emerging challenges?
Nyika et al.
J. Med. Ethics 2009;35:189-193.
ABSTRACT
| FULL TEXT
Sexual risk behaviour of the first cohort undergoing screening for enrolment into Phase I/II HIV vaccine trials in South Africa
Andersson et al.
Int J STD AIDS 2009;20:95-101.
ABSTRACT
| FULL TEXT
First trial of the HIV-1 vaccine in Africa: Ugandan experience
Mugerwa et al.
BMJ 2002;324:226-229.
FULL TEXT
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
Connor et al.
J. Virol. 1998;72:1552-1576.
ABSTRACT
| FULL TEXT
Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing Countries
Lurie and Wolfe
NEJM 1997;337:853-856.
FULL TEXT
The Emerging Genetic Diversity of HIV: The Importance of Global Surveillance for Diagnostics, Research, and Prevention
Hu et al.
JAMA 1996;275:210-216.
ABSTRACT
|
